Table 1.
Compound | Mechanism | Current study phase | Indication(s) |
---|---|---|---|
BIBR1532 | Small-molecule inhibitor of hTERT | Preclinical | Solid and hematologic malignancies |
UV1 | hTERT peptide vaccine | Phase 2 | Melanoma and NSCLC |
GX301 | hTERT peptide vaccine | Phase 2 | Prostate cancer |
AST-1 | hTERT-directed dendritic cell | Phase 1 | AML and prostate cancer |
VAC2 | hTERT-directed dendritic cell | Phase 2 | NSCLC |
IME | Oligonucleotide complementary to hTERT template | Phase 3 | MDS and MF |